A prominent Harvard Medical School professor has resigned from a U.S. Food and Drug Administration advisory panel in protest over the agency’s decision to approve Biogen Inc.’s Alzheimer’s drug Aduhelm.
In a powerful statement of disagreement with the Food and Drug Administration’s approval of Biogen’s controversial Alzheimer’s drug, three scientists have resigned from the independent committee that advised the agency on the treatment. “This might be the worst approval decision that the F.D.A. has made that I can remember,” said Dr. Aaron Kesselheim, a professor of medicine at Harvard Medical School and Brigham and Women’s Hospital, who.
Ogilvy and McCann heavyweight Andrew Schirmer has joined Syneos Health's GSW New York as president. Three members of the FDA panel that argued against aducanumab have quit in the wake of the Alzheimer's drug's approval. Inogen, recently equipped with a new CEO, has tapped BD vet Stanislav Glezer, M.D., as its chief medical officer.